Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial The Landmark Series: Systemic Therapy for Resectable Gastrointestinal Stromal Tumors The management of metastatic GIST: current standard and investigational therapeutics Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial Surgical Management of Metastatic Gastrointestinal Stromal Tumors
